


- 5 or a solvate thereof.
2. A pharmaceutical formulation according to claim 1 which comprises:  
one or more suspending agents.
3. A pharmaceutical formulation according to claim 2 wherein the suspending  
agent is microcrystalline cellulose and carboxy methylcellulose sodium.
- 10 4. A pharmaceutical formulation according to claim 2 wherein the suspending  
agent is present in an amount of between 0.1 and 5% (w/w), based on the  
total weight of the formulation.
5. A pharmaceutical formulation according to claim 1 which comprises:  
one or more preservatives.
- 15 6. A pharmaceutical formulation according to claim 5 wherein the preservative  
comprises benzalkonium chloride.
7. A pharmaceutical formulation according to claim 6 wherein the benzalkonium  
chloride is present within the formulation in an amount of between 0.001 and  
1% (w/w), based on the total weight of the formulation.
- 20 8. A pharmaceutical formulation according to claim 5 wherein the preservative  
comprises EDTA.
9. A pharmaceutical formulation according to claim 6 wherein the preservative  
also comprises EDTA.
10. A pharmaceutical formulation according to any claim 1 which comprises:  
25 one or more wetting agents.



11. A pharmaceutical formulation according to claim 10 wherein the wetting agent comprises polyoxyethylene (20) sorbitan monooleate.
12. A pharmaceutical formulation according to claim 11 wherein the polyoxyethylene (20) sorbitan monooleate is present within the formulation in an amount of between 0.001 and 0.05% (w/w), based on the total weight of the formulation.
13. A pharmaceutical formulation according to claim 1 which comprises: one or more isotonicity adjusting agents.
14. A pharmaceutical formulation according to claim 12 wherein the isotonicity adjusting agent comprises dextrose.
15. A pharmaceutical formulation according to claim 13 wherein dextrose is present within the formulation in an amount of between 0.1 and 10% (w/w), based on the total weight of the formulation.
16. A pharmaceutical formulation according to claim 1 characterised in that it is isotonic with fluids of the nasal cavity.
17. A pharmaceutical formulation to claim 1 which is buffered to a pH of between 5 and 7.
18. A pharmaceutical formulation according to claim 16 which is buffered using hydrochloric acid.
19. A pharmaceutical formulation according to claim 1 wherein the compound of formula (I) or solvate thereof is present within the formulation in an amount between 0.005% and 1% (w/w), based on the total weight of the formulation.
20. A pharmaceutical formulation according to claim 1 wherein the compound of formula (I) is used as unsolvated polymorph Form 1.
21. A pharmaceutical formulation according to claim 1 which comprises
- (i) one or more suspending agents;
  - (ii) one or more preservatives;
  - (iii) one or more wetting agents; and
  - (iv) one or more isotonicity adjusting agents
22. A pharmaceutical formulation according to claim 20 wherein: the suspending agent is microcrystalline cellulose and carboxy methylcellulose sodium, the preservative is EDTA and benzalkonium chloride, the wetting agent is

polyoxyethylene (20) sorbitan monooleate and the isotonicity adjusting agent is dextrose.

- 23  
22. A container comprising a pharmaceutical formulation according to claim 1 suitable for delivering it in the form of a nasal spray.
- 24  
5 23. A method of treatment of allergic rhinitis which comprises administering to a patient a pharmaceutically acceptable amount of a formulation according to claim 1.
- 25  
24. The method according to claim 23 wherein the administration is once-per-day.

10067020.020402